WallStSmart

MacroGenics Inc (MGNX)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MacroGenics Inc generates 21070% more annual revenue ($157.08M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -44.8%. MGNX earns a higher WallStSmart Score of 42/100 (D).

MGNX

Hold

42

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 4.0
Piotroski: 3/9Altman Z: -6.07

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MGNX2 strengths · Avg: 10.0/10
PEG RatioValuation
0.0110/10

Growing faster than its price suggests

Revenue GrowthGrowth
57.5%10/10

Revenue surging 57.5% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

MGNX4 concerns · Avg: 3.3/10
Price/BookValuation
11.8x4/10

Trading at 11.8x book value

Market CapQuality
$246.63M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.723/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MGNX

The strongest argument for MGNX centers on PEG Ratio, Revenue Growth. Revenue growth of 57.5% demonstrates continued momentum. PEG of 0.01 suggests the stock is reasonably priced for its growth.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : MGNX

The primary concerns for MGNX are Price/Book, Market Cap, Debt/Equity. Debt-to-equity of 1.72 is elevated, increasing financial risk.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

MGNX profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

MGNX is growing revenue faster at 57.5% — sustainability is the question.

MGNX generates stronger free cash flow (-36M), providing more financial flexibility.

Bottom Line

MGNX scores higher overall (42/100 vs 24/100) and 57.5% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MacroGenics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?